Ultragenyx reported a record $214 million in total revenue for Q2 2026, driven by strong sales of Crysvita and Dojolvi. The company reaffirmed its 2026 revenue guidance of $730-$760 million and expects combined R&D and SG&A expenses to remain flat or slightly decrease compared to 2025. Key upcoming catalysts include FDA decisions on two gene therapies and pivotal Phase 3 data for GTX-102 in Angelman syndrome, positioning Ultragenyx for growth and profitability in 2027. Cash reserves stood at $436 million as of June 30, 2026, supporting ongoing operations and development programs.
Taiwan's Taiex index reached a record intraday high of 48,601.53 driven by strong gains in the tech sector, especially semiconductor companies like TSMC, MediaTek, and Delta Electronics. This surge follows an AI-driven rally on Wall Street fueled by ...
China's lithium carbonate and spodumene spot prices fell significantly over the past month, influenced by the loss of license at CATL's Jianxiawo Mine, the country's largest lithium mine, which has returned to care and maintenance. Despite the price ...
Zcash (ZEC) price pulled back from a September peak near $1,590 to about $1,430, pausing after a strong rally. Institutional interest remains high, supported by Grayscale's Zcash ETF and a planned share split. The main issue is a debate over the Zcas...
Ethereum (ETH) has surpassed the $2500 resistance level, trading at $2,716.86 after a 5.7% rise in 24 hours, marking its strongest third quarter since 2016 with a 67.57% gain so far. This recovery follows two negative quarters in early 2026 where ETH...
Chinese President Xi Jinping is set to visit the U.S. from Wednesday to Friday, with several top American tech executives like Microsoft CEO Satya Nadella, Nvidia's Jensen Huang, and Apple's Tim Cook attending a key dinner in Washington, D.C. The Chi...
